<DOC>
	<DOCNO>NCT00004093</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy plus radiation therapy treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility concurrent chemoradiotherapy regimen paclitaxel vinorelbine standard chest radiotherapy patient locally advance non-small cell lung cancer . II . Determine maximum tolerate dose dose limit toxicity regimen patient population . III . Determine radiologic response rate induction chemotherapy carboplatin gemcitabine patient population . IV . Evaluate pathologic response rate patient undergoing resection . V. Evaluate time progression , overall survival , quality life patient population . OUTLINE : This dose escalation study vinorelbine . Patients receive induction chemotherapy consist carboplatin IV 30 minute day 1 follow gemcitabine IV 30 minute day 1 8 . Treatment repeat every 3 week 2 course . At 2 week follow completion induction chemotherapy , patient receive vinorelbine IV 10 minute follow paclitaxel IV 60 minute weekly radiotherapy daily 5 consecutive day week week 1-6 . Following initial induction chemotherapy , patient stable regressive disease may receive additional 2-4 course carboplatin gemcitabine investigator 's discretion . At approximately 2-6 week follow completion chemoradiotherapy , patient resectable/operable disease undergo surgical resection . Cohorts 3-6 patient receive escalate dos vinorelbine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 3 6 patient experience dose limit toxicity . Quality life assess patient . Patients follow 1 month . PROJECTED ACCRUAL : A total 38-47 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIA IIIB nonsmall cell lung cancer Pathologic stag mediastinal lymph node require ( N2 , N3 ) Bidimensionally measurable disease xray , CT scan , MRI OR Evaluable disease ( e.g. , pulmonary infiltrate evaluable xray ) No malignant pleural effusion PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 3 time ULN Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 50 mL/min Cardiovascular : No active cardiac ischemia No congestive heart failure Other : No significant active infection No severe complicate medical illness ( e.g. , severe neurologic psychiatric disease would prevent compliance ) No concurrent malignancy except nonmelanoma skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior pelvic thoracic radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>